Marianna Mancini

CIK: 0001838112

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)9 (56.3%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)7 (43.8%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

VKTX

Viking Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (16 total)

VKTX
Viking Therapeutics, Inc.
Jul 29, 2026
Sale(S)
Direct
18.2K shares at avg. $33.47$610K
VKTX
Viking Therapeutics, Inc.
Jul 28, 2026
Award(A)
Direct
31.7K shares-
VKTX
Viking Therapeutics, Inc.
Jan 5, 2026
Sale(S)
Direct
32K shares at avg. $32.29$1.0M
VKTX
Viking Therapeutics, Inc.
Jan 5, 2026
Sale(S)
Direct
13.6K shares at avg. $33.37$454K
VKTX
Viking Therapeutics, Inc.
Jan 5, 2026
Sale(S)
Direct
10.5K shares at avg. $34.22$359K
VKTX
Viking Therapeutics, Inc.
Jan 5, 2026
Sale(S)
Direct
1.6K shares at avg. $35.07$56K
VKTX
Viking Therapeutics, Inc.
Jan 2, 2026
Award(A)
Direct
32K shares-
VKTX
Viking Therapeutics, Inc.
Jan 2, 2026
Award(A)
Direct
41K shares-
VKTX
Viking Therapeutics, Inc.
Oct 28, 2025
Sale(S)
Direct
6.2K shares at avg. $35.00$216K
VKTX
Viking Therapeutics, Inc.
Oct 27, 2025
Award(A)
Direct
11.1K shares-
VKTX
Viking Therapeutics, Inc.
Jul 3, 2025
Sale(S)
Direct
4.3K shares at avg. $27.77$118K
VKTX
Viking Therapeutics, Inc.
Jul 2, 2025
Award(A)
Direct
7.7K shares-
VKTX
Viking Therapeutics, Inc.
Jan 6, 2025
Sale(S)
Direct
49.1K shares at avg. $42.69$2.1M
VKTX
Viking Therapeutics, Inc.
Jan 6, 2025
Sale(S)
Direct
5.1K shares at avg. $43.32$221K
VKTX
Viking Therapeutics, Inc.
Jan 3, 2025
Award(A)
Direct
44.5K shares-
VKTX
Viking Therapeutics, Inc.
Jan 3, 2025
Award(A)
Direct
21.7K shares-

		Type	Shares	Price		Ownership
Jul 29, 2026	VKTX Viking Therapeutics, Inc.	Sale(S)	18,217	$33.47	$609,636	Direct
Jul 28, 2026	VKTX Viking Therapeutics, Inc.	Award(A)	31,667	-	$0	Direct
Jan 5, 2026	VKTX Viking Therapeutics, Inc.	Sale(S)	31,961	$32.29	$1,032,110	Direct
Jan 5, 2026	VKTX Viking Therapeutics, Inc.	Sale(S)	13,600	$33.37	$453,876	Direct
Jan 5, 2026	VKTX Viking Therapeutics, Inc.	Sale(S)	10,500	$34.22	$359,303	Direct
Jan 5, 2026	VKTX Viking Therapeutics, Inc.	Sale(S)	1,600	$35.07	$56,117	Direct
Jan 2, 2026	VKTX Viking Therapeutics, Inc.	Award(A)	32,049	-	$0	Direct
Jan 2, 2026	VKTX Viking Therapeutics, Inc.	Award(A)	41,000	-	$0	Direct
Oct 28, 2025	VKTX Viking Therapeutics, Inc.	Sale(S)	6,185	$35.00	$216,492	Direct
Oct 27, 2025	VKTX Viking Therapeutics, Inc.	Award(A)	11,117	-	-	Direct
Jul 3, 2025	VKTX Viking Therapeutics, Inc.	Sale(S)	4,266	$27.77	$118,473	Direct
Jul 2, 2025	VKTX Viking Therapeutics, Inc.	Award(A)	7,667	-	-	Direct
Jan 6, 2025	VKTX Viking Therapeutics, Inc.	Sale(S)	49,115	$42.69	$2,096,685	Direct
Jan 6, 2025	VKTX Viking Therapeutics, Inc.	Sale(S)	5,100	$43.32	$220,914	Direct
Jan 3, 2025	VKTX Viking Therapeutics, Inc.	Award(A)	44,533	-	$0	Direct
Jan 3, 2025	VKTX Viking Therapeutics, Inc.	Award(A)	21,667	-	$0	Direct

1-16 of 16 transactions

About Mancini Marianna

Mancini Marianna (SEC CIK 0001838112) files insider reports with the SEC as Chief Operating Officer of Viking Therapeutics, Inc. (VKTX).

Signal8 holds 5 ownership filings by Mancini Marianna, all Form 4s, filed between Jan 6, 2025 and Jul 29, 2026. Those filings report 16 transactions, from Jan 3, 2025 to Jul 29, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Mancini Marianna's filings is in SAN DIEGO, CA.

Recent filings by Mancini Marianna

Jul 29, 2026: Open-market sale of VKTX shares (Form 4, code S).
Jul 28, 2026: Grant or award of VKTX shares (Form 4, code A).
Jan 5, 2026: Open-market sales of VKTX shares (4 lines, Form 4, code S).
Jan 2, 2026: Grants or awards of VKTX shares (2 lines, Form 4, code A).
Oct 28, 2025: Open-market sale of VKTX shares (Form 4, code S).

Other insiders filing for Viking Therapeutics, Inc. (VKTX)

Kelly-Gemmell Dorothy Elizabeth, Director
Lian Brian, President & CEO
ZANTE GREG, Chief Financial Officer
Chen Hubert C, Chief Medical Officer
Aubuchon Neil William, Chief Commercial Officer
SINGLETON J MATTHEW, Director

How to read Form 4 transaction codes